MediciNova, Inc.
MNOV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.26 | 0.21 | -0.19 | 0.40 |
| FCF Yield | -10.33% | -10.13% | -12.85% | -7.23% |
| EV / EBITDA | -4.97 | -2.31 | -5.66 | -5.85 |
| Quality | ||||
| ROIC | -23.87% | -15.66% | -20.57% | -12.06% |
| Gross Margin | 0.00% | 100.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 0.96 | 0.87 | 0.92 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -37.20% | – | – |
| Free Cash Flow Growth | -42.83% | 42.30% | -37.26% | 13.37% |
| Safety | ||||
| Net Debt / EBITDA | 3.17 | 5.14 | 1.22 | 6.93 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |